Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:213790.
doi: 10.1155/2014/213790. Epub 2014 May 15.

Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia

Affiliations

Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia

Claudia Bănescu et al. Biomed Res Int. 2014.

Abstract

The genetic polymorphisms of X-ray repair cross complementing group 1 (XRCC1), X-ray repair cross complementing group 3 (XRCC3), and xeroderma pigmentosum complementation group D (XPD) repair genes may lead to genetic instability and leukemogenesis. The purpose of the study was to evaluate the association between XRCC1 Arg399Gln, Arg280His and Arg194Trp, XRCC3 Thr241Met, and XPD Lys751Gln polymorphisms and the risk of developing CML in Romanian patients. A total of 156 patients diagnosed with CML and 180 healthy controls were included in this study. We found no association between CML and XRCC1 or XRCC3 variant genotypes in any of the investigated cases. A significant difference was observed in the variant genotype frequencies of the XPD Lys751Gln polymorphism between the patients with CML and control group (for variant homozygous genotypes, OR = 2.37; 95% CI = 1.20-4.67; P value = 0.016 and for combined heterozygous and variant homozygous genotypes, OR = 1.72; 95% CI = 1.10-2.69; P value = 0.019). This was also observed when analyzing the variant 751Gln allele (OR = 1.54; 95% CI = 1.13-2.11; P value = 0.008). Our results suggest that the XPD Lys751Gln variant genotype increases the risk of CML.

PubMed Disclaimer

References

    1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. The American Journal of Hematology. 2012;87(11):1037–1045. - PubMed
    1. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Letters. 2008;270(1):1–9. - PubMed
    1. D’Andrea AD. Targeting DNA repair pathways in AML. Best Practice and Research: Clinical Haematology. 2010;23(4):469–473. - PubMed
    1. Ronen A, Glickman BW. Human DNA repair genes. Environmental and Molecular Mutagenesis. 2001;37(3):241–283. - PubMed
    1. Braithwaite E, Wu X, Wang Z. Repair of DNA lesions: mechanisms and relative repair efficiencies. Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis. 1999;424(1-2):207–219. - PubMed

Publication types

Substances